Provided by Tiger Fintech (Singapore) Pte. Ltd.

MoonLake Immunotherapeutics

10.66
+0.40003.90%
Post-market: 10.660.00000.00%19:59 EDT
Volume:4.75M
Turnover:50.42M
Market Cap:684.70M
PE:-3.82
High:10.95
Open:10.26
Low:10.11
Close:10.26
52wk High:62.75
52wk Low:5.95
Shares:64.23M
Float Shares:24.16M
Volume Ratio:0.46
T/O Rate:19.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.7908
EPS(LYR):-1.8918
ROE:-40.34%
ROA:-24.99%
PB:1.94
PE(LYR):-5.63

Loading ...

Company Profile

Company Name:
MoonLake Immunotherapeutics
Exchange:
NASDAQ
Establishment Date:
2021
Employees:
- -
Office Location:
Dorfstrasse 29,Zug,Zug,Switzerland
Zip Code:
6300
Fax:
- -
Introduction:
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or axial spondyloarthritis. MoonLake Immunotherapeutics was incorporated in 2021 and is headquartered in Zug, Switzerland.

Directors

Name
Position
Bihua Chen
Chief Executive Officer and Chairwoman
John Schmid
Director
Nancy Chang
Director
Will Lewis
Director

Shareholders

Name
Position
Bihua Chen
Chief Executive Officer and Chairwoman
Andrew J. Phillips
Chief Financial Officer